Abstract |
We analyzed the methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter and mRNA expression in HL cells and assessed the response of these cells to dacarbazine. Expression of MGMT correlated with the presence of non-methylated promoters and cell lines with non-methylated promoters showed increased resistance against dacarbazine. KM-H2 cells expressed fusion transcripts between MGMT and proline-rich coiled-coil 2B (PRRC2B) but no wild type MGMT transcripts. Dacarbazine sensitivity suggested that fusion transcripts are translated into a protein with reduced functionality. MGMT promoter methylation predicts dacarbazine sensitivity of HL cells and it might be interesting to analyze this factor in HL patients.
|
Authors | Stefanie Kewitz, Martina Stiefel, Christof M Kramm, Martin S Staege |
Journal | Leukemia research
(Leuk Res)
Vol. 38
Issue 1
Pg. 138-43
(Jan 2014)
ISSN: 1873-5835 [Electronic] England |
PMID | 24284332
(Publication Type: Journal Article)
|
Copyright | Copyright © 2013 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antineoplastic Agents, Alkylating
- Purines
- Dacarbazine
- O(6)-Methylguanine-DNA Methyltransferase
- Azacitidine
- lomeguatrib
|
Topics |
- Antineoplastic Agents, Alkylating
(pharmacology)
- Azacitidine
(pharmacology)
- Cell Line, Tumor
- Cell Survival
(drug effects, genetics)
- DNA Methylation
- Dacarbazine
(antagonists & inhibitors, pharmacology)
- Drug Resistance, Neoplasm
(drug effects, genetics)
- Drug Synergism
- Gene Expression Regulation, Enzymologic
(drug effects)
- Gene Expression Regulation, Neoplastic
(drug effects)
- Hodgkin Disease
(genetics, metabolism, pathology)
- Humans
- Immunoblotting
- O(6)-Methylguanine-DNA Methyltransferase
(genetics, metabolism)
- Promoter Regions, Genetic
(genetics)
- Purines
(pharmacology)
- Reverse Transcriptase Polymerase Chain Reaction
|